P576 Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CD

Autor: G D'Haens, P Bossuyt, F Baert, T Molnár, E Clasquin, M Lowenberg, N Montazeri, H Peeters, G Lambrecht, S Vermeire

Publikováno v: Journal of Crohn's and Colitis. 17:i704-i705

Background Endoscopic healing is an important treatment goal in Crohn’s disease (CD). Vedolizumab (VDZ) was shown to induce endoscopic healing after 6 months in a significantly greater proportion of pts with early CD than in those with late CD (>2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e0e21817b7311b551eda50c5535d882
https://doi.org/10.1093/ecco-jcc/jjac190.0706

OP14 Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO

Autor: G D'Haens, C Taxonera, A Lopez-Sanroman, P Nos Mateu, S Danese, A Armuzzi, X Roblin, L Peyrin-Biroulet, R West, B Witteman, M Duijvestein, K Gecse, M Hulshoff, N Mostafavi, E Clasquin, Y Bouhnik, D Laharie

Publikováno v: Journal of Crohn's and Colitis. 17:i19-i19

Background Crohn’s disease (CD) is a chronic, immune-mediated inflammatory condition of the intestine, for which the majority of patients still needs to undergo surgical resection. Following the most common intervention ileocolonic resection, the v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::684f21a543a83340873377a3055037e8
https://doi.org/10.1093/ecco-jcc/jjac190.0014

High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial

Autor: Jessica R. de Bruyn, Peter Bossuyt, Marc Ferrante, Rachel L. West, Gerard Dijkstra, Ben J. Witteman, Manon Wildenberg, Frank Hoentjen, Denis Franchimont, Esmé Clasquin, Jarmila D. van der Bilt, Tim Tollens, Willem A. Bemelman, Andre D’Hoore, Marjolijn Duijvestein, Geert R. D’Haens, W. Bemelman, C. Buskens, E. Clasquin, J. De Bruyn, G. D’Haens, M. Duijvestein, J. Van der Bilt, B. Ferreira, S. Mulder, R. West, G. Dijkstra, A. Engelsman, J. Lange, L. Homans, B. Witteman, A. Eroglu-Berger, M. Russel, J. Jansen, T. Schakel–van den Berge, S. Cuppen, F. Hoentjen, A. Van Esch, D.J. De Jong, N. Mahmmod, W. Ten Hove.P. De Lange, R. Mallant, P. Houben, M. Ferrante, S. Vermeire, A. Outtier, T. Hermans, J. Lefrère, A. D’Hoore, K. Asnong, P. Bossuyt, I. Van de Schoot, B. Claerbout, G. Lambrecht, L. Boutaffala, C. Guebelle, E. Louis, D. Franchimont, V. Wambacq, A. Colard, A. Deflandre

Publikováno v: Clinical Gastroenterology and Hepatology, 19, 1573-1582.e5
Clinical Gastroenterology and Hepatology, 19, 8, pp. 1573-1582.e5
Clinical Gastroenterology and Hepatology, 19(8), 1573-1582.e5. ELSEVIER SCIENCE INC
Clinical gastroenterology and hepatology, 19(8), 1573-1582.e5. W.B. Saunders Ltd

BACKGROUND & AIMS: Vitamin D deficiency is common in Crohn's disease (CD). High-dose vitamin D had anti-inflammatory effects in preclinical studies and trials of patients with CD. We performed a randomized trial to determine whether high-dose vitamin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::745c4b94532c3a697791ed92464ebe3c
https://hdl.handle.net/2066/237041

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.